Terns Pharmaceuticals依据纳斯达克规则向新员工授予股权激励奖励

投资观察04-03

加州福斯特城，2026年4月2日——临床阶段肿瘤学公司Terns Pharmaceuticals, Inc.（简称"Terns"或"公司"）（纳斯达克代码：TERN）今日宣布，已于2026年4月1日根据修订后的《2022年入职激励奖励计划》条款，向三名新员工授予了股权激励奖励。该股权奖励已由公司董事会薪酬委员会依据纳斯达克上市规则5635(c)(4)批准，并作为员工接受Terns聘用的重要激励条件。

公司总计向新员工授予了23,316个限制性股票单位（RSUs），对应Terns普通股。这些RSUs将在四年内分期归属，前提是员工在相应归属日期前持续为公司服务。

关于Terns Pharmaceuticals

Terns Pharmaceuticals是一家临床阶段的肿瘤学公司，致力于通过重新构想已知生物学来开发具有重大影响力的药物。公司的领先项目TERN-701是一种高选择性、口服、变构的BCR-ABL抑制剂，具备潜在的最佳疾病治疗特性，有望在疗效、安全性和便利性方面显著优于现有慢性髓系白血病治疗方案。欲了解更多信息，请访问：www.ternspharma.com。

Terns联系方式

投资者 Justin Ng investors@ternspharma.com

媒体 Jenna Urban CG Life media@ternspharma.com

（完）道琼斯通讯社 2026年4月2日16:05 ET（20:05 GMT）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1191183612?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-03 04:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191183612","market":"us","top_or_hot":-1,"title":"Terns Pharmaceuticals依据纳斯达克规则向新员工授予股权激励奖励","media":"投资观察","content":"<p>加州福斯特城，2026年4月2日——临床阶段肿瘤学公司Terns Pharmaceuticals, Inc.（简称\"Terns\"或\"公司\"）（纳斯达克代码：TERN）今日宣布，已于2026年4月1日根据修订后的《2022年入职激励奖励计划》条款，向三名新员工授予了股权激励奖励。该股权奖励已由公司董事会薪酬委员会依据纳斯达克上市规则5635(c)(4)批准，并作为员工接受Terns聘用的重要激励条件。</p>\n<p>公司总计向新员工授予了23,316个限制性股票单位（RSUs），对应Terns普通股。这些RSUs将在四年内分期归属，前提是员工在相应归属日期前持续为公司服务。</p>\n<p>关于Terns Pharmaceuticals</p>\n<p>Terns Pharmaceuticals是一家临床阶段的肿瘤学公司，致力于通过重新构想已知生物学来开发具有重大影响力的药物。公司的领先项目TERN-701是一种高选择性、口服、变构的BCR-ABL抑制剂，具备潜在的最佳疾病治疗特性，有望在疗效、安全性和便利性方面显著优于现有慢性髓系白血病治疗方案。欲了解更多信息，请访问：www.ternspharma.com。</p>\n<p>Terns联系方式</p>\n<p>投资者\nJustin Ng\ninvestors@ternspharma.com</p>\n<p>媒体\nJenna Urban\nCG Life\nmedia@ternspharma.com</p>\n<p>（完）道琼斯通讯社\n2026年4月2日16:05 ET（20:05 GMT）</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Terns Pharmaceuticals依据纳斯达克规则向新员工授予股权激励奖励</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTerns Pharmaceuticals依据纳斯达克规则向新员工授予股权激励奖励\n</h2>\n\n<h4 class=\"meta\">\n\n2026-04-03 04:06 北京时间&nbsp;&nbsp;&nbsp;<strong>投资观察</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>加州福斯特城，2026年4月2日——临床阶段肿瘤学公司Terns Pharmaceuticals, Inc.（简称\"Terns\"或\"公司\"）（纳斯达克代码：TERN）今日宣布，已于2026年4月1日根据修订后的《2022年入职激励奖励计划》条款，向三名新员工授予了股权激励奖励。该股权奖励已由公司董事会薪酬委员会依据纳斯达克上市规则5635(c)(4)批准，并作为员工接受Terns聘用的重要激励条件...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"","article_id":"1191183612","we_media_id":"1076224072","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191183612","pubTimestamp":1775160411,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"投资观察","introduction":"关注海外资本市场一手动态","home_visible":1,"id":"1076224072","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"加州福斯特城，2026年4月2日——临床阶段肿瘤学公司Terns Pharmaceuticals, Inc.今日宣布，已于2026年4月1日根据修订后的《2022年入职激励奖励计划》条款，向三名新员工授予了股权激励奖励。该股权奖励已由公司董事会薪酬委员会依据纳斯达克上市规则5635批准，并作为员工接受Terns聘用的重要激励条件。公司总计向新员工授予了23,316个限制性股票单位，对应Terns普通股。Terns Pharmaceuticals是一家临床阶段的肿瘤学公司，致力于通过重新构想已知生物学来开发具有重大影响力的药物。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","BK4566":"资本集团","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","TERN":"Terns Pharmaceuticals, Inc.","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU1791807156.HKD":"BGF WORLD FINANCIALS \"A2\" (HKDHDG) ACC","LU0314106906.USD":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","BK4504":"桥水持仓","BK4559":"巴菲特持仓","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","CUL3":"Leverage Shares 3x Long Copper ETC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","BK4588":"碎股","BK4007":"制药","BK4207":"综合性银行","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU0106831901.USD":"贝莱德世界金融基金A2","C":"花旗","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓"},"translate_title":"Terns Pharmaceuticals grants equity incentive awards to new hires under Nasdaq rules","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TERN":1,"CUL3":1,"C":1,"NQmain":1},"content_text":"加州福斯特城，2026年4月2日——临床阶段肿瘤学公司Terns Pharmaceuticals, Inc.（简称\"Terns\"或\"公司\"）（纳斯达克代码：TERN）今日宣布，已于2026年4月1日根据修订后的《2022年入职激励奖励计划》条款，向三名新员工授予了股权激励奖励。该股权奖励已由公司董事会薪酬委员会依据纳斯达克上市规则5635(c)(4)批准，并作为员工接受Terns聘用的重要激励条件。\n公司总计向新员工授予了23,316个限制性股票单位（RSUs），对应Terns普通股。这些RSUs将在四年内分期归属，前提是员工在相应归属日期前持续为公司服务。\n关于Terns Pharmaceuticals\nTerns Pharmaceuticals是一家临床阶段的肿瘤学公司，致力于通过重新构想已知生物学来开发具有重大影响力的药物。公司的领先项目TERN-701是一种高选择性、口服、变构的BCR-ABL抑制剂，具备潜在的最佳疾病治疗特性，有望在疗效、安全性和便利性方面显著优于现有慢性髓系白血病治疗方案。欲了解更多信息，请访问：www.ternspharma.com。\nTerns联系方式\n投资者\nJustin Ng\ninvestors@ternspharma.com\n媒体\nJenna Urban\nCG Life\nmedia@ternspharma.com\n（完）道琼斯通讯社\n2026年4月2日16:05 ET（20:05 GMT）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1191183612","isCrawlerRequest":true}